• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

COVID-19 Vaccine Exposure and Newborn Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Pregnant women were excluded from COVID-19 vaccine trials 
    • Newborn outcomes data remains limited 
  • Goldshtein et al. (JAMA Pediatrics, 2022) examined whether BNT162b2 mRNA (Pfizer) vaccination during pregnancy is associated with adverse neonatal and early infant outcomes  

METHODS: 

  • Population-based cohort study 
    • Maccabi Healthcare Services database | 2.5-million-member state-mandated health fund in Israel 
  • Population 
    • All singleton live births 
    • Between March and September 2021  
  • Exposures 
    • Maternal BNT162b2 mRNA (Pfizer) vaccination during pregnancy 
  • Study design 
    • Risk ratios (RR) were calculated for all primary outcomes 
    • Adjustments: Maternal age | Timing of conception | Parity | Socioeconomic status | Population subgroup | Maternal influenza immunization status 
  • Primary outcomes 
    • Preterm birth 
    • Small birth weight for gestational age (SGA) 
    • Congenital malformations 
    • All-cause hospitalizations 
    • Infant death 

RESULTS: 

  • 24,288 newborns 
    • 49% female | 96% born at ≥37 weeks gestation 
    • Vaccine exposed in first trimester: 2134 
    • Vaccine exposed in second trimester: 9364 
  • No significant differences in any of the primary outcomes between exposed and unexposed newborns 
    • Preterm birth rates  
      • RR 0.95 (95% CI, 0.83 to 1.10) 
    • SGA 
      • RR 0.97 (95% CI, 0.87 to 1.08) 
    • All cause neonatal hospitalizations 
      • RR 0.99 (95% CI, 0.83 to 1.12) 
    • Postneonatal hospitalizations after birth 
      • RR 0.95 (95% CI, 0.84 to 1.07) 
    • Congenital anomalies 
      • RR 0.69 (95% CI, 0.44 to 1.04) 
    • Infant mortality 
      • RR 0.84 (95% CI, 0.43 to 1.72) 

CONCLUSION: 

  • In this large population-based study, no significant adverse effects of COVID-19 vaccination during pregnancy were found for newborns 
  • Limitations include observational design, although an RCT would likely be considered unethical based on all the data suggesting significant benefit during pregnancy  
  • The authors state 

Despite limitations, these findings contribute to current evidence in establishing the safety of BNT162b2 to offspring and can be used to inform pregnant patients, couples planning pregnancy, and counseling physicians 

Robust assessments of maternal and offspring safety are important to reduce vaccine hesitancy and increase confidence among pregnant women 

  • Prenatal vaccine exposure is likely safe for newborns 

Learn More – Primary Sources: 

Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Latest Data on Transplacental Antibody Transfer Following COVID-19 Vaccination
COVID-19 Vaccination Does Not Increase Risk of Preterm Birth or SGA
Vaccines in Pregnant and Lactating Women: Is Immune Response Similar to that of Non-Pregnant Patients?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site